Literature DB >> 21195789

TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways.

Matthias J Duechs1, Christian Hahn, Ewald Benediktus, Melanie Werner-Klein, Armin Braun, Heinz Gerd Hoymann, Florian Gantner, Klaus J Erb.   

Abstract

Toll-like receptor (TLR) mediated signaling induces pro-inflammatory responses and can both suppress and exacerbate allergic responses in the airways. The aim of our study was to directly compare the efficacy of different TLR agonists in inhibiting or exacerbating the development of Th2-mediated responses in the airways and investigate if the suppressive effects were associated with increased pro-inflammatory responses. Mice were immunized on day 0, 14 and 21 by intraperitoneal injection of ovalbumin/alum and exposed to ovalbumin aerosol on day 26 and 27. TLR2, TLR3, TLR4, TLR7 and TLR9 agonists (0.001, 0.01, 0.1, or 1 mg/kg) were administered intratracheally 1 h before each allergen exposure. Both the TLR7 and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg. The TLR2 and TLR4 agonists potentiated eosinophilia. All TLR agonists enhanced neutrophil numbers at doses as low as 0.01 mg/kg, in particular TLR2 and TLR4 agonists. TLR7 and TLR9 agonists also significantly reduced IL-4 and IL-5 levels and all TLR agonists, with the exception of TLR7, enhanced the amount IL-1β, IL-6, and TNF-α detected in the whole lung lavage. Only application of TLR9 agonist induced detectable levels of IL-10 in the lung. Suppressive effects of the TLR agonists were not dependent upon IFN-γ and IL-10 or associated with increased numbers of Foxp3(+)CD4(+) Tr cells in the lavage fluid. Airway resistance was reduced significantly only when TLR7 agonist was administered. When applied therapeutically 2 days after allergen exposure, all TLR agonists, except TLR2, similarly reduced airway eosinophilia and IL-4 levels. Taken together our results show that TLR7 agonists had the strongest anti-asthmatic effects with the lowest pro-inflammatory potential, suggesting that activating TLR7 may have the greatest potential to treat allergic disorders in humans.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195789     DOI: 10.1016/j.pupt.2010.12.009

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  21 in total

1.  An inactivated Pseudomonas aeruginosa medicament inhibits airway allergic inflammation and improves epithelial functions.

Authors:  Yurong Tan; Huijun Liu; Huihui Yang; Lili Wang; Xiaoqun Qin
Journal:  J Physiol Sci       Date:  2012-09-26       Impact factor: 2.781

Review 2.  Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets.

Authors:  Vikas Mishra; Jaspreet Banga; Patricia Silveyra
Journal:  Pharmacol Ther       Date:  2017-08-23       Impact factor: 12.310

Review 3.  Pattern-recognition receptors in human eosinophils.

Authors:  Anne Månsson Kvarnhammar; Lars Olaf Cardell
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

4.  Upping the antedrug: is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?

Authors:  E H Kaufman; D B Jacoby
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity.

Authors:  Damir Matesic; Aleksander Lenert; Petar Lenert
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

Review 6.  Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma.

Authors:  Brittany E Givens; Sean M Geary; Aliasger K Salem
Journal:  Immunotherapy       Date:  2018-03-23       Impact factor: 4.196

Review 7.  The therapeutic potential of Toll-like receptor 7 stimulation in asthma.

Authors:  Matthew G Drake; Elad H Kaufman; Allison D Fryer; David B Jacoby
Journal:  Inflamm Allergy Drug Targets       Date:  2012-12

8.  Severity of allergic airway disease due to house dust mite allergen is not increased after clinical recovery of lung infection with Chlamydia pneumoniae in mice.

Authors:  Pavel Dutow; Sandra Lingner; Robert Laudeley; Silke Glage; Heinz-Gerd Hoymann; Anna-Maria Dittrich; Beate Fehlhaber; Meike Müller; Armin Braun; Andreas Klos
Journal:  Infect Immun       Date:  2013-07-01       Impact factor: 3.441

9.  Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores.

Authors:  Michael Hessenberger; Richard Weiss; Esther E Weinberger; Christof Boehler; Josef Thalhamer; Sandra Scheiblhofer
Journal:  Vaccine       Date:  2012-12-27       Impact factor: 3.641

10.  Prophylactic mRNA Vaccination against Allergy Confers Long-Term Memory Responses and Persistent Protection in Mice.

Authors:  E Hattinger; S Scheiblhofer; E Roesler; T Thalhamer; J Thalhamer; R Weiss
Journal:  J Immunol Res       Date:  2015-10-18       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.